Drug intelligence / Profile preview

JBM TC4

Development stage: Phase 2
Lead developer: Joben Bio-Medical
Modality: Small Molecules
Administration: Topical

Overview

JBM TC4 is a botanical (herbal) drug developed by Joben Bio-Medical for the prevention and reduction of radiodermatitis in breast cancer patients undergoing radiotherapy. It is classified as a new molecular entity and falls under herbal medicines, ketones, lactams, skin disorder therapies, and spiro compounds. The precise mechanism of action has not been defined. Clinical development has reached Phase II for the prevention and treatment of acute radiation-induced dermatitis in breast cancer patients[1][2][3][7].

Other names: JBM-TC4JBM-TC-4JBM-TC 4

Beyond the preview

Go deeper on JBM TC4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JBM TC4.

Explore the full profile